Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1a clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-06-04 |
2024-03 |
0 |
N/A |
N/A |
N/A |
2024-05-07 |
2023-12 |
-0.52 |
N/A |
N/A |
N/A |
2023-11-14 |
2023-09 |
-0.92 |
-0.64 |
0.28 |
30.43% |
2023-08-15 |
2023-06 |
-0.52 |
-0.69 |
-0.17 |
-32.69% |
2023-05-16 |
2023-03 |
-0.85 |
-0.78 |
0.07 |
8.24% |
2023-03-30 |
2022-12 |
-1.4 |
N/A |
N/A |
N/A |
Date |
Name |
Relation |
Quantity |
Description |
2022-06-13 |
BROIDRICK AMY S |
President |
34.50K |
Purchase |
2020-03-11 |
DOYLE NOAH J |
Director |
0.00 |
Sale |
2020-04-09 |
FOEHR MATTHEW W |
Director |
138.64K |
Stock Award(Grant) |
2017-10-02 |
JAVELIN VENTURE PARTNERS, L.P. |
Beneficial Owner of more than 10% of a Class of Security |
7.05M |
Purchase |
2021-08-18 |
KRUGER KURT H |
Director |
18.00K |
Purchase |
2021-04-15 |
LOTZ CHRISTOPHER L |
Chief Financial Officer |
12.54K |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Blackrock Inc. |
25.84K |
23.54K |
0.51% |
2023-06-29 |
Geode Capital Management, LLC |
22.15K |
20.18K |
0.44% |
2023-06-29 |
State Street Corporation |
10.93K |
9.96K |
0.22% |
2023-09-29 |
Highmark Wealth Management LLC |
8.01K |
8.09K |
0.16% |
2023-06-29 |
Tower Research Capital LLC (TRC) |
4.61K |
4.20K |
0.09% |
2023-06-29 |
UBS Group AG |
1.37K |
1.25K |
0.03% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-05-30 |
Fidelity Extended Market Index Fund |
11.85K |
10.93K |
0.23% |
2023-05-30 |
Fidelity NASDAQ Composite Index Fund |
4.89K |
4.51K |
0.10% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
2.93K |
2.70K |
0.06% |
2023-05-30 |
Fidelity Total Market Index Fund |
1.51K |
1.40K |
0.03% |
Split |
Date |
1 : 10 |
2022-11-23 |
1 : 25 |
2020-05-26 |
1 : 10 |
2018-03-23 |